New York, Feb 6, 2026, 12:56 (EST) — Regular session
AbbVie (ABBV.N) shares rose $4.43, or about 2%, to $223.45 in midday trading on Friday, steadying after a choppy week for large drugmakers. The stock traded between $218.51 and $225.81 earlier in the session.
The move follows AbbVie’s quarterly update on Wednesday, when it forecast 2026 adjusted profit above Wall Street expectations but still drew a sharp selloff after a key drug’s sales came in light. “Investors continue to have concerns about growing competition,” William Blair analyst Matt Phipps said, flagging pressure in inflammatory bowel disease as Johnson & Johnson’s (JNJ.N) Tremfya pushes deeper into the market. Chief Financial Officer Scott Reents told analysts the company still expects “low-single-digit pricing headwinds” for Skyrizi and Rinvoq in 2026 and beyond. Reuters
AbbVie said fourth-quarter net revenues rose 10% to $16.618 billion and adjusted diluted profit was $2.71 per share. Skyrizi generated $5.006 billion in the quarter and Rinvoq brought in $2.374 billion, while Humira sales fell 25.9% to $1.246 billion as biosimilar competition continued to bite. “2025 was another outstanding year for AbbVie,” Chief Executive Robert Michael said in the results release. SEC
The broader healthcare tape was firmer, with the Health Care Select Sector SPDR Fund (XLV) up about 1%. Johnson & Johnson’s shares were little changed in midday trade.
Some analysts argued the quarter’s upside leaned heavily on Humira’s surprise resilience, even as the company works to shift its growth story to newer immunology drugs. David Risinger of Leerink Partners wrote that “the vast majority of revenue upside” came from Humira, while Cantor Fitzgerald’s Carter Gould said the profit range “should be viewed positively” but that investors are likely to press harder on product-level guides, particularly Skyrizi. BioPharma Dive
Drug pricing also snapped back into focus after President Donald Trump launched the TrumpRx.gov discount drug website on Thursday, an initiative tied to “most-favored nation” pricing — a push to match the lowest prices paid abroad. Reuters reported Japanese drugmaker shares fell on the news as investors weighed what wider discounting could mean for the sector. Reuters
AbbVie’s earnings release also flagged a string of regulatory and deal updates that it says widen its growth platform beyond immunology. The company said it won FDA approval of Epkinly in combination for relapsed or refractory follicular lymphoma, and submitted applications for a new Rinvoq indication in vitiligo; it also disclosed an exclusive licensing agreement with RemeGen for an investigational PD-1/VEGF-targeted bispecific antibody and a deal to acquire a device manufacturing facility from West Pharmaceutical Services.
But the company’s own call laid out the same pressure points behind Wednesday’s volatility: Humira erosion continues, and AbbVie faces economic headwinds in its aesthetics business even as it leans on Botox and other newer franchises to carry growth. The company also pointed to ongoing competitive and regulatory risks that could squeeze pricing across portfolios.
For the next hard numbers, AbbVie told analysts it expects 2026 net revenues of about $67 billion, up 9.5%, and guided for first-quarter net revenues of roughly $14.7 billion. It forecast first-quarter adjusted EPS of $2.97 to $3.01.
Investors now want cleaner proof that Rinvoq and Skyrizi can keep outgrowing the Humira slide as rivals crowd the market and Washington keeps drug pricing in the headlines. On the calendar, AbbVie’s next quarterly dividend — raised to $1.73 per share — is payable on Feb. 17, the company has said.
